An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Completed · Phase 1/Phase 2

Conditions studied: Advanced Cancer

In brief

The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

Key facts

Study ID

NCT03994601

Run by

Bristol-Myers Squibb

People needed

219

Starts

2019-09-06

Expected to finish

2024-08-31

Last updated by the study team

2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
• Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies

You may not qualify if…

• Active, known or suspected autoimmune disease
• Active malignancy requiring concurrent intervention
• Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0075 — Costa Mesa, California, United States
• Local Institution - 0050 — Orange, California, United States
• Local Institution - 0005 — Aurora, Colorado, United States
• Local Institution - 0002 — Baltimore, Maryland, United States
• Local Institution - 0004 — St Louis, Missouri, United States
• Local Institution - 0001 — Hackensack, New Jersey, United States
• Local Institution - 0011 — Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
• Local Institution - 0074 — Buenos Aires, Buenos Aires F.D., Argentina
• Local Institution - 0014 — Córdoba, Córdoba Province, Argentina
• Local Institution - 0013 — Río Cuarto, Córdoba Province, Argentina
• Local Institution - 0008 — ABB, Distrito Federal, Argentina
• Local Institution - 0012 — CABA, Distrito Federal, Argentina
• Local Institution - 0017 — Buenos Aires, Argentina
• Local Institution - 0016 — Buenos Aires, Argentina
• Local Institution - 0006 — Toronto, Ontario, Canada
• Local Institution - 0042 — Montreal, Quebec, Canada
• Local Institution - 0046 — Montreal, Quebec, Canada
• Local Institution - 0036 — Santiago, Santiago Metropolitan, Chile
• Local Institution - 0019 — Santiago, Santiago Metropolitan, Chile
• Local Institution - 0035 — Santiago, Santiago Metropolitan, Chile
• Local Institution - 0009 — Santiago, Santiago Metropolitan, Chile
• Local Institution - 0010 — Viña del Mar, Valparaiso, Chile
• Local Institution - 0034 — Bordeaux, Gironde, France
• Local Institution - 0022 — Saint-Herblain, Loire-Atlantique, France
• Local Institution - 0018 — Bron, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.